Abstract
Nitric oxide (NO), a mediator of various physiological and pathophysiological processes, is synthesized by three isozymes of nitric oxide synthase (NOS). Potential candidate clinical drugs should be devoid of inhibitory activity against endothelial NOS (eNOS), since eNOS plays an important role in maintaining normal blood pressure and flow. A new series of aminopiperidines as potent inhibitors of iNOS were identified from a HTS lead. From this study, we identified compound 33 as a potent iNOS inhibitor, with >25-fold selectivity over eNOS and 16-fold selectivity over nNOS.
MeSH terms
-
Amines / chemical synthesis*
-
Amines / chemistry
-
Amines / pharmacology*
-
Binding Sites
-
Drug Design
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Inhibitory Concentration 50
-
Models, Molecular
-
Nitric Oxide Synthase Type I / antagonists & inhibitors
-
Nitric Oxide Synthase Type I / metabolism
-
Nitric Oxide Synthase Type II / antagonists & inhibitors*
-
Nitric Oxide Synthase Type II / metabolism
-
Nitric Oxide Synthase Type III / antagonists & inhibitors
-
Nitric Oxide Synthase Type III / metabolism
-
Piperidines / chemical synthesis*
-
Piperidines / chemistry
-
Piperidines / pharmacology*
-
Structure-Activity Relationship
Substances
-
Amines
-
Enzyme Inhibitors
-
Piperidines
-
NOS3 protein, human
-
Nitric Oxide Synthase Type I
-
Nitric Oxide Synthase Type II
-
Nitric Oxide Synthase Type III